Medpace Holdings is experiencing a normalization from peak growth, with revenue growth decelerating from 32.0% in Q4 2025 to 17.2% in Q2 2026, yet it continues to outpace peers. The company maintains robust profitability with operating margins around 20.8% and...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated to 17.2% YoY in Q2 2026 from a peak of 32.0% in Q4 2025, while gross margin contracted to 28.5% from 33.2% a year earlier, though operating margin remained stable at 20.8%.
Medpace Holdings' full-service CRO model provides comprehensive clinical research solutions, driving efficiency and client retention.
The company's disciplined capital allocation and financial management have contributed to robust operational execution and stock appreciation.
Medpace Holdings is well-positioned to capitalize on the expanding biotech sector, leveraging its proprietary technology and expertise.
Trailing total returns as of 10/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 21, 2026 | $4.84+9.0% vs $4.44 | $716M+0.2% vs $714M |
Q3 2026 Jul 22, 2026 | $4.25+6.8% vs $3.98 | $707M+2.6% vs $690M |
Q2 2026 Apr 22, 2026 | $4.28+9.2% vs $3.92 | $707M+1.3% vs $698M |
Q1 2026 Feb 9, 2026 | $4.67+11.5% vs $4.19 | $708M+2.8% vs $689M |
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.
Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer against potential cash flow volatility as biotech funding rebounds.
Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.
Benchmark MEDP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Medpace Holdings, Inc. (MEDP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $669.20 | $18.68B | 43.80 | 19.97% | 17.83% | 70.23% | — | |
| $185.27 | $14.19B | 63.89 | -0.37% | 3.99% | 3.54% | — | |
| $345.37 | $16.64B | -118.68 | -0.85% | -5.96% | -7.63% | — | |
| $25.00 | $1.29B | 25.25 | -2.67% | 6.04% | 4.95% | — | |
| $27.71 | $6.18B | 54.33 | 59% | -5.51% | -30.03% | — | |
| $279.36 | $45.98B | 35.63 | 5.87% | 8.1% | 21.51% | — |
Medpace Holdings, Inc. (MEDP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Medpace Holdings, Inc. (MEDP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 21, 2026·SEC
Jul 22, 2026·SEC
Jun 4, 2026·SEC
Get notified when MEDP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Medpace Holdings, Inc. (MEDP) stock FAQ — growth, dividends, profitability & financials explained
Medpace Holdings, Inc. (MEDP) reported $2.84B in revenue for fiscal year 2025. This represents a 879% increase from $290.0M in 2014.
Medpace Holdings, Inc. (MEDP) grew revenue by 20.0% over the past year. This is strong growth.
Yes, Medpace Holdings, Inc. (MEDP) is profitable, generating $517.8M in net income for fiscal year 2025 (17.8% net margin).
Medpace Holdings, Inc. (MEDP) has a return on equity (ROE) of 70.2%. This is excellent, indicating efficient use of shareholder capital.
Medpace Holdings, Inc. (MEDP) generated $667.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
